FDA Biosimilars Meeting Seeks Input On Product Naming, Foreign Data And Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
Two-day public hearing in November will cover nearly all aspects of the new pathway except the patent challenge mechanism.
You may also be interested in...
Biosimilars: FDA's Meeting Notice Upgrades Safety To "Paramount"
Updated outline of November meeting discussion points includes several tweaks to the pharmacovigilance section.
Biosimilars: FDA's Meeting Notice Upgrades Safety To "Paramount"
Updated outline of November meeting discussion points includes several tweaks to the pharmacovigilance section.
Biosimilar Road Bump: Teva Filgrastim's Complete Response Shows Even Full BLAs Can Stumble
FDA issued a complete response letter requesting "several items" from Teva to finish review of its biological license application.